The threat of new tariffs on drugmakers has set off a debate within the biotech industry over whether to cut voluntary ...

Smaller acquisitions and disciplined pricing are proving to be big benefits to a wider number of companies ...

Iovance Biotherapeutics argues that there is a meaningful opportunity here of more than 8,000 patients diagnosed annually in ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

He said U.S. losses alone top $500 billion a year and called gene drives “the only scalable” solution. As reported by 24/7 ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

Mantis takes disparate sources of data to make synthetic datasets that can be used to build so-called "digital twins" of the ...